Glatiramer Acetate Patent Expiration
Glatiramer Acetate is Used for treating multiple sclerosis. It was first introduced by Teva Pharmaceuticals Usa
Glatiramer Acetate Patents
Given below is the list of patents protecting Glatiramer Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Copaxone | US8232250 | Low frequency glatiramer acetate therapy | Aug 19, 2030 | Teva Pharms Usa |
| Copaxone | US8399413 | Low frequency glatiramer acetate therapy | Aug 19, 2030 | Teva Pharms Usa |
| Copaxone | US8969302 | Low frequency glatiramer acetate therapy | Aug 19, 2030 | Teva Pharms Usa |
| Copaxone | US9155776 | Low frequency glatiramer acetate therapy | Aug 19, 2030 | Teva Pharms Usa |
| Copaxone | US9402874 | Low frequency glatiramer acetate therapy | Aug 19, 2030 | Teva Pharms Usa |
| Copaxone | US5981589 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US6054430 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US6054430 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US6342476 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US6362161 | Copolymer-1 improvements on compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US6362161 | Copolymer-1 improvements on compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US6620847 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US6939539 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US7199098 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US7199098 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US8367605 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US8367605 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
Glatiramer Acetate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Glatiramer Acetate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS | Mapi Pharma Ltd. | NA |
COMPLETED
(Jul 1, 2026)
| PHASE3 |
| Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS | Mapi Pharma Ltd. | NA |
TERMINATED
(Apr 1, 2026)
| PHASE2 |